Moderna’s 2022 Shot Orders Edge Up Amid Easing Pandemic

Orders for Moderna Inc.'s Covid-19 vaccine rose only modestly in the last six weeks as it battles rivals for market share amid fading pandemic concerns, although the company is still waiting to see whether the U.S. places new booster orders for later this year.

The messenger RNA vaccine maker said it has signed $19 billion worth of agreements for 2022 sales of its shot, up from $18.5 billion announced in January. But the company also said in an quarterly earnings statement that options for 2022 orders were $3 billion, down from $3.5 billion announced earlier. 

Still, Chief Executive Officer Stephane Bancel said on a conference call that the U.S. government has yet to put in new orders for 2022. That suggests there is room for the numbers to grow later this year if the U.S. decides to buy a large amount of booster doses.

Moderna also announced a $3 billion share repurchase program. The shares rose as much as 12% as of 10:09 a.m. in New York. They had lost almost half their value before today since the year began.

Covid case numbers are plummeting around the world as the omicron wave recedes, while new vaccine makers such as Novavax Inc. enter the market. As countries relax pandemic restrictions, Moderna is working to retain momentum in sales of its only product.

For the quarter, earnings were $11.29 a share on revenues of $7.21 billion. Analysts had estimated earnings of $10.17 a share and revenue of $6.84 billion. The company said final 2021 sales of its Covid vaccine, its only product, were $17.7 billion, slightly above the $17.5 billion preliminary product sales number announced in January.

Moderna has been racing with rival mRNA partners Pfizer Inc. and BioNTech SE to ramp up Covid vaccine production and sell shots around the world. Pfizer has said it has $32 billion in 2022 orders for its Covid vaccine.

Key variables in Moderna's future sales include whether fourth doses will be widely used and whether variant-specific boosters, which both Moderna and Pfizer are testing, will prove useful. On a conference call with analysts, Moderna officials said they continue to believe that a fourth booster dose will be needed by the fall of 2022.

Moderna also said it's working on a shot that would combine its existing Covid vaccine with the omicron-specific version that's in testing.

Overall, about 807 million vaccine doses were shipped worldwide in 2021, Moderna said.

©2022 Bloomberg L.P.

Unlock this article for free
Sign up to access exclusive stories, fewer ads, and a personalised experience.
Set as Trusted Source
on Google Search